Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?



Status:Recruiting
Conditions:Diabetes, Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:25 - 70
Updated:4/21/2016
Start Date:July 2013
End Date:December 2016
Contact:Sidika E Kasim-Karakas, M.D.
Email:sekarakas@ucdavis.edu
Phone:(530)752-6254

Use our guide to learn which trials are right for you!

The purpose of this study is to investigate whether intake of protein supplement just before
meals lowers the blood sugar levels after the meals. It is believe that pre-meal
administration of a high-protein supplement can effectively improve glycemic control in type
2 diabetes (DM).

11.3% of the population aged 20 years or older (25.6 million individuals) has diabetes. In
the population aged 65 years or older, the prevalence of diabetes reaches to 26.9%.

Type 2 DM is caused by insulin resistance accompanied by insufficient compensatory insulin
response. Therefore insulin secretagogues are a significant component of the therapeutic
armamentarium. Insulin secretagogues, such as sulphonylureas and meglitinides, are routinely
prescribed to lower post prandial glucose levels in type 2 DM. However, these medications
are cleared by the liver and the kidneys and cannot be used in the presence of relevant
co-morbidities. These medicines can also cause side effects, including hypoglycemia.
Limitations of these medicines are likely to lead diabetic patients and their health care
providers to seek alternate methods to treat postprandial hyperglycemia. Thus, our research
which aims to identify an alternate insulin secretagogue is important and timely.

Whey protein (WP), a rich source of essential and branch chain (BC) amino acids (AA), is a
potent insulin secretagogue. Although it is well known that protein and/or AA intakes
stimulate insulin secretion, protein supplements are not being used clinically in order to
lower post-prandial glycemia. WP can be a satisfactory alternative to the pharmaceutical
insulin secretagogues.

Inclusion Criteria:

- Men and women with type 2 DM; age: 25 to 70y; BMI: 25 - 40 kg/m2; on no drug
treatment or on metformin alone; HgBA1 6.5 - 8.5%; urinary microalbumin < 30 mg/g cr.

Exclusion Criteria:

- Systemic disease (liver, renal, untreated hypothyroidism, etc); in the last 2 mo: >
5% weight change, smoking, alcohol intake > 4 /wk; restricted diets; medications or
herbals affecting insulin secretion/sensitivity . Pregnant women, prisoners,
individuals who cannot provide informed consent.
We found this trial at
1
site
?
mi
from
Sacramento, CA
Click here to add this to my saved trials